Abstract
We assessed infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 mug/ml. All six urinary infections responded to treatment regardless of susceptibility.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Bacterial Infections / drug therapy
-
Bacterial Infections / microbiology
-
Escherichia coli / drug effects*
-
Escherichia coli / enzymology
-
Escherichia coli / isolation & purification
-
Female
-
Humans
-
Klebsiella oxytoca / drug effects*
-
Klebsiella oxytoca / enzymology
-
Klebsiella oxytoca / isolation & purification
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / enzymology
-
Klebsiella pneumoniae / isolation & purification
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Penicillanic Acid / analogs & derivatives
-
Penicillanic Acid / pharmacology
-
Penicillanic Acid / therapeutic use
-
Piperacillin / pharmacology
-
Piperacillin / therapeutic use
-
Piperacillin, Tazobactam Drug Combination
-
Retrospective Studies
-
Time Factors
-
Treatment Outcome
-
Urinary Tract Infections / drug therapy
-
Urinary Tract Infections / microbiology
-
beta-Lactamase Inhibitors*
Substances
-
Anti-Bacterial Agents
-
beta-Lactamase Inhibitors
-
Piperacillin, Tazobactam Drug Combination
-
Penicillanic Acid
-
Piperacillin